SG11201908527SA - High affinity mage-a1-specific tcrs and uses thereof - Google Patents
High affinity mage-a1-specific tcrs and uses thereofInfo
- Publication number
- SG11201908527SA SG11201908527SA SG11201908527SA SG11201908527SA SG 11201908527S A SG11201908527S A SG 11201908527SA SG 11201908527S A SG11201908527S A SG 11201908527SA SG 11201908527S A SG11201908527S A SG 11201908527SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- seattle
- washington
- avenue
- pct
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000009258 tissue cross reactivity Effects 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471956P | 2017-03-15 | 2017-03-15 | |
| PCT/US2018/022759 WO2018170338A2 (en) | 2017-03-15 | 2018-03-15 | High affinity mage-a1-specific tcrs and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908527SA true SG11201908527SA (en) | 2019-10-30 |
Family
ID=63523985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908527S SG11201908527SA (en) | 2017-03-15 | 2018-03-15 | High affinity mage-a1-specific tcrs and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11034748B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3595708A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7037577B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102375033B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110582299A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018234830B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019018863A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3055983A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201992131A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL269250A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019010972A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201908527SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018170338A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2891321T3 (es) | 2016-04-08 | 2022-01-27 | Adaptimmune Ltd | Receptores de células T |
| DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| NZ754365A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | Novel t cell receptors and immune therapy using the same |
| AU2018234830B2 (en) * | 2017-03-15 | 2023-03-02 | Fred Hutchinson Cancer Center | High affinity MAGE-A1-specific TCRs and uses thereof |
| MA52536A (fr) | 2018-04-19 | 2021-02-24 | Baylor College Medicine | Reprogrammation de lymphocytes t cd4 en lymphocytes cd8 cytotoxiques par expression forcée de récepteurs de lymphocytes t restreints à cd8ab et de classe 1 |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| TWI850360B (zh) | 2019-04-04 | 2024-08-01 | 德商梅迪基因免疫治療公司 | 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途 |
| AU2020264484A1 (en) | 2019-05-01 | 2021-11-04 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using a CDB engineered T cell therapy |
| KR102776925B1 (ko) | 2019-06-25 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Flt3l-fc 융합 단백질 및 사용 방법 |
| GB201915282D0 (en) | 2019-10-22 | 2019-12-04 | Immunocore Ltd | Specific binding molecules |
| CR20220396A (es) | 2020-02-14 | 2022-11-14 | Jounce Therapeutics Inc | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos |
| CN111320703A (zh) * | 2020-03-11 | 2020-06-23 | 北京双赢科创生物科技有限公司 | 靶向cd22的嵌合抗原受体及其应用 |
| CN111499763A (zh) * | 2020-03-31 | 2020-08-07 | 江苏省省级机关医院 | 一种靶向mage-a1的特异性全人源嵌合抗原受体及其应用 |
| AU2021270378A1 (en) * | 2020-05-13 | 2022-12-15 | Adaptimmune Limited | Method of treatment of cancer or tumour |
| CN112194719A (zh) * | 2020-09-01 | 2021-01-08 | 中日友好医院(中日友好临床医学研究所) | Crt抗原和mage-a1抗原的制备及其应用 |
| WO2022076353A1 (en) | 2020-10-06 | 2022-04-14 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating mage-a1-expressing disease |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CA3201767A1 (en) | 2020-12-14 | 2022-06-23 | Thomas M. Schmitt | Compositions and methods for cellular immunotherapy |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| BR112023021034A2 (pt) * | 2021-04-14 | 2023-12-12 | Tscan Therapeutics Inc | Proteínas de ligação que reconhecem antígeno ha-2 e usos dos mesmos |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4430402A1 (en) | 2021-11-09 | 2024-09-18 | T-Knife GmbH | Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| ES2999273T3 (en) | 2022-03-17 | 2025-02-25 | Gilead Sciences Inc | Ikaros zinc finger family degraders and uses thereof |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| CN116063457A (zh) * | 2022-04-27 | 2023-05-05 | 恒瑞源正(广州)生物科技有限公司 | Mage-a1特异性t细胞受体及其用途 |
| CN119317638A (zh) * | 2022-06-01 | 2025-01-14 | 北京可瑞生物科技有限公司 | Mage-a1特异性tcr及其用途 |
| NL2032130B1 (en) * | 2022-06-10 | 2023-12-18 | Academisch Ziekenhuis Leiden | T cell receptors directed against melanoma-associated antigen and uses thereof |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| TW202519517A (zh) | 2023-07-26 | 2025-05-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025081123A1 (en) | 2023-10-12 | 2025-04-17 | Fred Hutchinson Cancer Center | Methods and compositions for improving t cell immunotherapy |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025146286A1 (en) * | 2024-01-04 | 2025-07-10 | Immunoscape Pte. Ltd. | Human t cell receptors and uses thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596536B1 (en) * | 1991-02-08 | 2003-07-22 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US20030148973A1 (en) * | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
| EP1485475B2 (en) | 2002-03-15 | 2017-09-20 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| CA2514517A1 (en) | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
| US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| GB0511124D0 (en) * | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
| ATE549401T1 (de) | 2005-10-18 | 2012-03-15 | Prec Biosciences | Rational konstruierte meganukleasen mit veränderter sequenzspezifität und dna- bindungsaffinität |
| US20080064631A1 (en) * | 2006-01-13 | 2008-03-13 | Jeffrey Molldrem | T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease |
| WO2008039969A2 (en) * | 2006-09-28 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| CN101668853B (zh) * | 2007-03-05 | 2013-07-31 | 株式会社癌免疫研究所 | 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用 |
| KR101319499B1 (ko) | 2008-02-22 | 2013-10-17 | 엘지디스플레이 주식회사 | 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법 |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| US8785601B2 (en) * | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US9228007B1 (en) * | 2010-03-11 | 2016-01-05 | The Regents Of The University Of California | Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells |
| WO2011146121A1 (en) | 2010-05-17 | 2011-11-24 | Sangamo Biosciences, Inc. | Novel dna-binding proteins and uses thereof |
| ME02810B (me) * | 2010-09-20 | 2018-01-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t ćelijski receptori i t ćelijski epitopi |
| WO2012054825A1 (en) | 2010-10-22 | 2012-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3 t cell receptors and related materials and methods of use |
| JP6066909B2 (ja) * | 2011-06-28 | 2017-01-25 | 株式会社癌免疫研究所 | ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子 |
| EP2756094B1 (en) | 2011-08-15 | 2017-12-27 | Medlmmune, LLC | Anti-b7-h4 antibodies and their uses |
| CN102295702B (zh) * | 2011-08-26 | 2014-01-29 | 中国科学院微生物研究所 | 一种针对t细胞受体可变区特异性单抗的制备方法 |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| WO2013176772A1 (en) | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| IL237315B (en) | 2012-08-20 | 2022-07-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| JP6401704B2 (ja) | 2012-10-10 | 2018-10-10 | サンガモ セラピューティクス， インコーポレイテッド | Ｔ細胞を修飾する化合物およびその使用 |
| EP2921557B1 (en) | 2012-12-12 | 2016-07-13 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| US10377808B2 (en) * | 2013-01-29 | 2019-08-13 | Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch | High avidity antigen recognizing constructs |
| US10000546B2 (en) * | 2013-03-13 | 2018-06-19 | Health Research, Inc. | Compositions and method for use of recombinant T cell receptors for direct recognition of tumor antigen |
| WO2015066262A1 (en) | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| AU2014350051A1 (en) | 2013-11-18 | 2016-07-07 | Crispr Therapeutics Ag | CRISPR-Cas system materials and methods |
| AU2014352826B2 (en) * | 2013-11-22 | 2019-08-01 | The Board Of Trustees Of The University Of Illinois | Engineered high-affinity human T cell receptors |
| CA2942459C (en) * | 2014-04-01 | 2023-03-07 | Biontech Cell & Gene Therapies Gmbh | Claudin-6-specific immunoreceptors and t cell epitopes |
| US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
| EP2944652A1 (en) * | 2014-05-13 | 2015-11-18 | Technische Universität München | Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma |
| US10538572B2 (en) * | 2014-08-04 | 2020-01-21 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for WT-1 |
| CN106804108B (zh) | 2014-09-12 | 2021-08-10 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
| CA2961179A1 (en) * | 2014-09-14 | 2016-03-17 | Washington University | Personalized cancer vaccines and methods therefor |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| RU2732042C2 (ru) | 2015-02-19 | 2020-09-10 | Компьюджен Лтд. | Анти-pvrig антитела и способы применения |
| AU2016258845B2 (en) * | 2015-05-01 | 2022-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| CN106188274A (zh) * | 2015-05-06 | 2016-12-07 | 广州市香雪制药股份有限公司 | 识别rhamm抗原短肽的t细胞受体 |
| EP3303591B1 (en) * | 2015-06-01 | 2019-04-03 | Medigene Immunotherapies GmbH | T cell receptor library |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| CN105316362B (zh) * | 2015-08-19 | 2020-03-17 | 暨南大学 | 一种Dual-RMCE介导的TCR基因置换系统及其方法 |
| CN106749620B (zh) * | 2016-03-29 | 2020-09-25 | 广东香雪精准医疗技术有限公司 | 识别mage-a1抗原短肽的t细胞受体 |
| JP6989138B2 (ja) * | 2016-06-17 | 2022-01-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | Ｔ細胞受容体及びその使用 |
| DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| DE102016123847B3 (de) * | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| AU2018234830B2 (en) * | 2017-03-15 | 2023-03-02 | Fred Hutchinson Cancer Center | High affinity MAGE-A1-specific TCRs and uses thereof |
-
2018
- 2018-03-15 AU AU2018234830A patent/AU2018234830B2/en not_active Withdrawn - After Issue
- 2018-03-15 JP JP2019550622A patent/JP7037577B2/ja not_active Expired - Fee Related
- 2018-03-15 CA CA3055983A patent/CA3055983A1/en active Pending
- 2018-03-15 EP EP18767104.5A patent/EP3595708A4/en not_active Withdrawn
- 2018-03-15 SG SG11201908527S patent/SG11201908527SA/en unknown
- 2018-03-15 KR KR1020197029977A patent/KR102375033B1/ko not_active Expired - Fee Related
- 2018-03-15 WO PCT/US2018/022759 patent/WO2018170338A2/en not_active Ceased
- 2018-03-15 BR BR112019018863A patent/BR112019018863A8/pt not_active Application Discontinuation
- 2018-03-15 CN CN201880026621.3A patent/CN110582299A/zh active Pending
- 2018-03-15 EA EA201992131A patent/EA201992131A1/ru unknown
- 2018-03-15 MX MX2019010972A patent/MX2019010972A/es unknown
-
2019
- 2019-09-10 IL IL26925019A patent/IL269250A/en unknown
- 2019-09-13 US US16/571,013 patent/US11034748B2/en active Active
-
2020
- 2020-12-22 US US17/131,688 patent/US20210355189A1/en not_active Abandoned
-
2021
- 2021-03-12 JP JP2021039957A patent/JP2021090462A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200017568A1 (en) | 2020-01-16 |
| KR20190129082A (ko) | 2019-11-19 |
| IL269250A (en) | 2019-11-28 |
| JP2021090462A (ja) | 2021-06-17 |
| BR112019018863A8 (pt) | 2023-05-02 |
| WO2018170338A2 (en) | 2018-09-20 |
| CN110582299A (zh) | 2019-12-17 |
| EA201992131A1 (ru) | 2020-02-06 |
| EP3595708A2 (en) | 2020-01-22 |
| CA3055983A1 (en) | 2018-09-20 |
| US11034748B2 (en) | 2021-06-15 |
| WO2018170338A3 (en) | 2019-11-21 |
| JP2020509767A (ja) | 2020-04-02 |
| KR102375033B1 (ko) | 2022-03-15 |
| JP7037577B2 (ja) | 2022-03-16 |
| AU2018234830B2 (en) | 2023-03-02 |
| EP3595708A4 (en) | 2020-12-16 |
| BR112019018863A2 (pt) | 2020-04-14 |
| US20210355189A1 (en) | 2021-11-18 |
| MX2019010972A (es) | 2019-12-02 |
| AU2018234830A1 (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
| SG11201901642XA (en) | Constitutively active cytokine receptors for cell therapy | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201805268XA (en) | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201810076WA (en) | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety | |
| SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
| SG11201908784TA (en) | Improved antigen binding receptor formats |